AQS.V - Aequus Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.1400
-0.0100 (-6.67%)
At close: 3:21PM EST
Stock chart is not supported by your current browser
Previous Close0.1500
Open0.1500
Bid0.1350 x 0
Ask0.1400 x 0
Day's Range0.1300 - 0.1500
52 Week Range0.1200 - 0.2450
Volume480,201
Avg. Volume82,760
Market Cap11.261M
Beta (3Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-0.0340
Earnings DateMay 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
  • GlobeNewswire

    Aequus Provides Third Quarter 2019 Financial Highlights

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended September 30, 2019 (“Q3 2019”) and associated Company developments. “Aequus has continued to advance the business in Q3, signing a key collaboration with Medicom Healthcare which adds a collection of market-ready ophthalmology products along with late-stage development assets to our growing ophthalmology franchise in Canada,” said Doug Janzen, Charmain and CEO of Aequus.

  • Imagine Owning Aequus Pharmaceuticals (CVE:AQS) While The Price Tanked 56%
    Simply Wall St.

    Imagine Owning Aequus Pharmaceuticals (CVE:AQS) While The Price Tanked 56%

    Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...

  • GlobeNewswire

    Aequus Highlights Study Indicating Vistitan as the Most Effective Treatment for Glaucoma

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) today acknowledged the research results presented at the American Academy of Ophthalmology in San Francisco that revealed bimatoprost 0.03%, branded as PrVistitanTM  and promoted by Aequus in Canada, as the most efficacious topical treatment currently available for glaucoma and ocular hypertension in terms of intraocular pressure. The study, conducted by Dr. Paul Harasymowycz and his team, assessed the comparative efficacy of latanoprostene bunod to other treatments for intraocular pressure reduction at three months.

  • GlobeNewswire

    Aequus Replaces Expired Short Form Base Shelf Prospectus

    Aequus Pharmaceuticals Inc. (TSX-V : AQS, OTCQB : AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that, further to its press release dated August 27, 2019, it has received a receipt for its final short form base shelf prospectus (the “Prospectus”). The Prospectus will allow Aequus to offer, subject to the filing of a shelf prospectus supplement, up to C$20,000,000 of common shares, preferred shares, debt securities, subscription receipts, units and warrants from time to time, in each of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario, until the Prospectus expires on October 16, 2021.

  • Should You Worry About Aequus Pharmaceuticals Inc.'s (CVE:AQS) CEO Pay?
    Simply Wall St.

    Should You Worry About Aequus Pharmaceuticals Inc.'s (CVE:AQS) CEO Pay?

    Doug Janzen has been the CEO of Aequus Pharmaceuticals Inc. (CVE:AQS) since 2014. First, this article will compare CEO...

  • GlobeNewswire

    A Return to Revenue Growth - Aequus Provides Second Quarter 2019 Financial Highlights

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the six months ended June 30, 2019 (“Q2 2019”) and associated Company developments. “We’re pleased to announce a return to revenue growth in the second quarter,” said Doug Janzen, Charmain and CEO of Aequus.

  • GlobeNewswire

    Aequus Signs Exclusive Distribution Agreement with Medicom Healthcare for Canadian Distribution Rights of Ophthalmic Products

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of an exclusive distribution agreement with Medicom Healthcare Ltd. (“Medicom”), a United Kingdom based pharmaceutical company with a focus on preservative free therapies in ophthalmology. Under the distribution agreement, Aequus will receive commercial rights to novel portions of Medicom’s portfolio of ophthalmology products including the Evolve® line of preservative free dry eye products within Canada.

  • Do Directors Own Aequus Pharmaceuticals Inc. (CVE:AQS) Shares?
    Simply Wall St.

    Do Directors Own Aequus Pharmaceuticals Inc. (CVE:AQS) Shares?

    If you want to know who really controls Aequus Pharmaceuticals Inc. (CVE:AQS), then you'll have to look at the makeup...

  • GlobeNewswire

    Aequus Provides First Quarter 2019 Financial Highlights

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three months ended March 31, 2019 (“Q1 2019”) and associated Company developments. “Aequus continues to drive its promotional efforts forward with Q1 2019 unit growth of 27% and 5.3% over Q1 2018 in our main revenue drivers, Vistitan and Tacrolimus, respectively,” said Doug Janzen, Chairman and CEO of Aequus. The decrease is attributable to a contractual step down in profit share for both Tacrolimus and PRVistitan™ (“Vistitan”).

  • GlobeNewswire

    Aequus to Clarify Press Release of 23rd May 2019 Relating to Zepto Capsulotomy System and Kensington Eye Institute

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) confirms its release of 23rd May 2019. Aequus is pleased to be a supplier of the Zepto Capsulotomy System (“the Product”) with the Kensington Eye Institute in Ontario, Canada.

  • GlobeNewswire

    Aequus to supply Kensington Eye Institute with Zepto Capsulotomy system; Extends Distribution Agreement with Mynosys

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce an agreement for the Zepto Precision Pulse Capsulotomy device (“Zepto”) with The Kensington Eye Institute, a world renowned clinic and leader in Canada for cataract, glaucoma, and retina surgery. Additionally, Aequus is pleased to announce the extension of the Zepto distribution agreement with Mynosys, which prolongs the term to April, 2022.

  • GlobeNewswire

    Aequus Closes $2.35 Million Offering of Convertible Debenture Units

    Aequus Pharmaceuticals Inc. (“Aequus” or the “Company”) (AQS.V) (AQSZF) is pleased to announce that it has closed its previously announced offering (the “Offering”) of convertible debenture units of the Company (the “Convertible Debenture Units”) at a price of $1,000 per Convertible Debenture Unit (the “Offering Price”) for aggregate gross proceeds to the Company of $2,348,000. The Offering was led by Mackie Research Capital Corporation as lead agent and sole bookrunner (the “Agent”).

  • GlobeNewswire

    Aequus to Present at Bloom Burton & Co. Healthcare Investor Conference on May 1, 2019

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced that its Chairman and Chief Executive Officer, Doug Janzen, will present at the eighth annual Bloom Burton & Co. Healthcare Investor Conference on Wednesday May 1st, 2019 at 2:30pm ET in Hall A at the Metro Toronto Convention Centre in Toronto, Ontario. Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products.

  • Some Aequus Pharmaceuticals (CVE:AQS) Shareholders Have Copped A Big 63% Share Price Drop
    Simply Wall St.

    Some Aequus Pharmaceuticals (CVE:AQS) Shareholders Have Copped A Big 63% Share Price Drop

    If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough on longer term Aequus Pharmaceuticals Inc. (CVE:AQS) shareholders. So they might be feeling emotional abou...

  • GlobeNewswire

    Aequus Announces Filing of Prospectus Supplement and an Update to Previously Announced Public Offering of Convertible Debenture Units

    Aequus Pharmaceuticals Inc. (the “Company”) (AQS.V) (AQSZF) is pleased to announce that it has filed a prospectus supplement (the “Prospectus Supplement”) to its short form base shelf prospectus dated August 15, 2017 (the “Base Shelf Prospectus”) relating to its previously announced marketed public offering of convertible debenture units of the Company (each, a “Debenture Unit”) at a price of $1,000 per Debenture Unit for gross proceeds of up to $3 million (the “Offering”). The Prospectus Supplement was filed with the securities regulatory authorities in each of the provinces of British Columbia, Alberta, Manitoba, Saskatchewan and Ontario. The confirmed terms of the Offering are that each Debenture Unit will consist of a 9.5% unsecured convertible debenture (each, a “Convertible Debenture”) with a maturity of 36 months from the date of issuance (the “Maturity Date”) and 2,380 common share purchase warrants (each, a “Warrant”), exercisable for 36 months from the date of issuance.

  • GlobeNewswire

    Aequus Provides Financial Year End Financial Highlights

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the full year ended December 31, 2018. “2018 was our strongest year to date,” said Doug Janzen, Chairman and CEO of Aequus. “We achieved quarter over quarter revenue growth in all four quarters of the year for our commercial business, with Q4 revenue surpassing $500,000 for the first time before a one-time adjustment was applied.

  • CNW Group

    IIROC Trading Resumption - AQS

    VANCOUVER , April 3, 2019 /CNW/ - Trading resumes in: Company: Aequus Pharmaceuticals Inc. TSX-Venture Symbol: AQS (All Issues) Resumption (ET): 11:00 AM IIROC can make a decision to impose a temporary ...

  • GlobeNewswire

    Aequus Announces Public Offering of Convertible Debenture Units

    Aequus Pharmaceuticals Inc. (the “Company”) (AQS.V) (AQSZF) is pleased to announce that it expects to file a preliminary prospectus supplement (the “Prospectus Supplement”) to its short form base shelf prospectus dated August 15, 2017 (the “Base Shelf Prospectus”) relating to a proposed marketed public offering of convertible debenture units of the Company (each, a “Debenture Unit”) at a price of $1,000 per Debenture Unit for gross proceeds of approximately $3 million (the “Offering”). The indicative terms of the Offering are that each Debenture Unit will consist of a 9.5% unsecured convertible debenture (each, a “Convertible Debenture”) with a maturity of 36 months from the date of issuance (the “Maturity Date”) and an indicative amount of common share purchase warrants (each, a “Warrant”) representing 50% warrant coverage, exercisable for 36 months from the date of issuance.

  • CNW Group

    IIROC Trading Halt - AQS

    VANCOUVER , April 3, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Aequus Pharmaceuticals Inc. TSX-Venture Symbol: AQS (All Issues) Reason: At the Request of the Company Pending ...

  • GlobeNewswire

    Aequus Signs Term Sheet with European Partner for a Preservative Free Therapeutic in Ophthalmology  

    Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) is pleased to announce the signing of a term sheet for an exclusive license in Canada of an undisclosed preservative free ophthalmic therapeutic with a European partner. The preservative free therapeutic is a prescription product, currently approved in certain countries in Europe. Aequus has previously met with Health Canada to receive regulatory guidance regarding this therapeutic and expects to submit an application for regulatory approval in the second half of 2019 for this product, with minimal additional analytical data required to complete the data package.